FBR Remains Positive on Galectin Therapeutics' (GALT) Prospects in NASH-CX; Affirms at 'Market Perform'
Tweet Send to a Friend
FBR affirms Galectin Therapeutics Inc. (NASDAQ: GALT) at Market Perform with a price target of $2 following Q3 results and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
